TWST Twist Bioscience Inc Projected Price to Earnings
Twist Bioscience (TWST) strives for global leadership in synthetic biology by leveraging silicon platforms for DNA data storage. The business's forward P/E clearly demonstrates market expectations, with the ratio currently standing at 0.00. High process automation minimizes human error, while an eco-friendly approach reduces plastic and chemical consumption, driving a breakthrough in medicine.
Analytical breakdowns and data insights for company Twist Bioscience Corp (TWST)
- stock value and consensus price forecast:
- market capitalization data:
- issuer book value statistics:
- debt and solvency information:
Total Debt to Capital Twist Bioscience|TWST - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Twist Bioscience|TWST - Company Cumulative Debt|Debt to Book Capitalization Ratio Twist Bioscience Inc|TWST - Long-Term Debt Volume|Company Short-Term Debts Twist Bioscience|Quick Ratio twistbioscience.com
- financial results and valuation multiples details:
TWST - Net Financial Result|Projected Future Earnings Twist Bioscience|TWST - Market Cap to Earnings|Future Price to Earnings Twist Bio|TWST - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Twist Bioscience Inc|TWST - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Twist Bioscience|TWST - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months twistbioscience.com|TWST - Net earnings per one share growth for the current year|Expected earnings per share growth for next year Twist Bioscience
Analysis of all company metrics:TWST Twist Bioscience, Inc.
Twist Bioscience (TWST) combines proprietary DNA synthesis with multi-cloud hosting to minimize infrastructure risks. The ratio of the current market price to expected annual net income determines the asset's calculated value. This metric allows investors to assess the premium paid for future growth. Low values signal undervaluation but may indicate a value trap. The dynamics of these processes are reflected in the company's forward P/E for the coming year.
Main competitors
Future Price to Earnings Tempus Labs (TEM)|Market Cap to Projected Earnings Qiagen NV|Ionis Pharma - Projected Price to Earnings|Market Cap to Future Earnings Ratio RGEN (Repligen Inc.)|RNA: Projected Price to Earnings|Future Price to Earnings Multiple CRSP (crisprtx.com)|WGS: Forward P/E Multiple|RARE (Ultragenyx Pharmaceutical Inc.) - Future Price to Earnings|BEAM (Beam Therapeutics Corp) - Forward P/E Multiple|Sarepta Corp (SRPT) - Market Cap to Projected Earnings|Future Price to Earnings 10x Genomics, Inc. (TXG)|NTLA - Projected Price to Earnings Ratio|Future Price to Earnings Stoke Therapeutics, Inc. STOK|Market Cap to Projected Earnings BioLife Solutions Inc (BLFS)|Wave Life Sciences Corp - Forward P/E Multiple|Maze Therapeutics Corp (MAZE) - Projected Price to Earnings|SION: Forward P/E Multiple|PRME - Market Cap to Projected Earnings|TSHA (Taysha Gene Therapies, Inc.) - Forward P/E Multiple|Projected Price to Earnings Ratio uniQure NV QURE|Future Price to Earnings MeiraGTx PLC (MGTX)|REGENXBIO Corp - Price to Future Earnings Ratio|Forward P/E Multiple SLDB (Solid Biosciences Inc.)|OCGN - Projected Price to Earnings|PacBio - Forward P/E Multiple|Projected Price to Earnings Ratio Benitec Biopharma Inc|DSGN (Design Pharma) - Projected Price to Earnings|RCKT: Market Cap to Future Earnings Ratio|Projected Price to Earnings FDMT|Projected Price to Earnings Lexeo (LXEO)|Future Price to Earnings Korro Bio, Inc. (KRRO)|Market Cap to Projected Earnings Editas Medicine Inc|Silence Therapeutics Inc. - Projected Price to Earnings|Market Cap to Future Earnings Ratio PRQR (ProQR)|Codexis Bio - Forward P/E Multiple|SGMO (sangamo.com) - Price to Future Earnings Ratio|nautilus.bio (NAUT) - Future Price to Earnings|Price to Future Earnings Ratio MGX|DTIL (Precision BioSciences, Inc.) - Forward P/E Multiple|Forward P/E Multiple Generation Bio Corp|Projected Price to Earnings BOLD (Boundless Bio, Inc.)|Market Cap to Future Earnings Ratio XCUR|Imunon - Projected Price to Earnings|PHIO - Projected Price to Earnings|Mustang Bio Corp - Forward P/E Multiple|Market Cap to Projected Earnings TransCode Therapeutics RNAZ|bionanogenomics.com (BNGO) - Future Price to Earnings|APDN - Market Cap to Projected Earnings|Projected Price to Earnings BLUE|IPA (ImmunoPrecise) - Market Cap to Future Earnings Ratio|Projected Price to Earnings OMGA (Omega)|OMIC (Singular Genomics Corp) - Future Price to Earnings Multiple|Forward P/E Multiple RGLS (Regulus Therapeutics)|syros.com - Future Price to Earnings|Telesis Bio - Forward P/E Multiple|Market Cap to Projected Earnings TRACON Pharmaceuticals Inc. TCON|Unity Bio (UBX) - Future Price to Earnings
